Scholars@Duke

• Background
• 

  Education, Training, & Certifications

  • Fellow in Hematology-Oncology, Medicine, Duke University 2004 - 2007
  • Medical Resident, Medicine, University of Texas at Dallas 2001 - 2004
  • M.D., University of North Carolina - Chapel Hill 2001
• 

  Duke Appointment History

  • Associate Professor of Medicine, Medicine, Medical Oncology, Medicine 2019 - 2020
  • Assistant Professor of Medicine, Medicine, Medical Oncology, Medicine 2010 - 2019
  • Medical Instructor in the Department of Medicine, Medicine, Medical Oncology, Medicine 2007 - 2010
  • Instructor, Temporary in the Department of Medicine, Medicine, Medical Oncology, Medicine 2007
• Research
• 

  Selected Grants

  • Synthetic lethality by targeting the core senescent mechanism in lung cancer. awarded by National Institutes of Health 2020 - 2025
  • Targeting convergent oncogenic signaling during AR inhibition to overcome metastasis and immune evasion in prostate cancer awarded by National Institutes of Health 2019 - 2024
  • Global Measurements of Protein Folding Stability for Characterization of Aging and Disease awarded by National Institutes of Health 2019 - 2023
  • Epigenomic Reprogramming in Patient Derived Models of Colorectal Cancer awarded by National Institutes of Health 2018 - 2023
  • Inhibition of CaMKK2 sensitizes rectal cancers to radiation therapy awarded by National Institutes of Health 2021 - 2022
  • Therapeutic targeting of MESH1 in renal cell carcinoma awarded by Department of Defense 2020 - 2022
  • Targeting tumor-specific apoptosis regulation in advanced ER+ breast cancer awarded by Department of Defense 2019 - 2022
  • Medical Scientist Training Program awarded by National Institutes of Health 1997 - 2022
  • Anonymous Donation 2020 - 2021
  • Targeting KRAS (G12C) Mutant in Colorectal Cancer 2018 - 2021
  • Development of an Organoid/MicroOrganoid Biobank with matching TILs (Tumor Infiltrating Lymphocytes) to Correlate Response to Therapy 2020 - 2021
  • Targeting the p38/Snail/PD-L1 axis in hormone-therapy resistance and metastasis awarded by Department of Defense 2018 - 2021
  • Therapeutic targeting of cystine addiction of renal cell carcinoma awarded by Department of Defense 2019 - 2021
  • Understanding methionine metabolism and its therapeutic potential in cancer awarded by National Institutes of Health 2019 - 2021
  • Selectively targeting apoptosis in PIK3CA mutant colorectal cancers awarded by National Institutes of Health 2016 - 2021
  • Targeting plasma membrane spatial dynamics to suppress aberrant Wnt signaling awarded by Texas A&M University 2020 - 2021
  • Determining the Efficacy of Liposomal Gemcitabine in Patient Derived Xenografts (PDXs) 2017 - 2019
  • Identifying gene-environment interactions that confer metabolic vulnerabilities in cancer awarded by National Institutes of Health 2018 - 2019
  • Targeting differential apoptosis regulation in triple negative breast cancer awarded by Department of Defense 2016 - 2019
  • Targeting the TK1 receptor in colorectal and lung PDX using CarT cell and Motorcar cell 2017 - 2019
  • Role of the Stroma in Fibrolamellar Hepatocellular Carcinoma 2016 - 2019
  • Using bacterial CRISPR/Cas endonucleases to selectively eliminate HPV-transformed cells in vivo awarded by National Institutes of Health 2015 - 2017
  • Targeting Calreticulin in Colorectal Cancer Liver Metastasis awarded by National Institutes of Health 2015 - 2017
  • Development and Validation of Novel Therapeutic Targets in Anal Cancer 2015 - 2016
  • Aptamer Targeted Drug and Toxin Delivery to Prostate Cancer awarded by Department of Defense 2014 - 2016
  • A Platform for Real-time Drug Profiling of Patient-Derived Melanomas awarded by National Institutes of Health 2014 - 2016
  • In Vivo Selection of Tumor-Specific RNA Binding Motifs awarded by National Institutes of Health 2011 - 2015
  • Administrative Supplement for Recruitment of New Faculty awarded by National Cancer Institute 2009 - 2011
• 

  External Relationships

  • AccuBeing LLC
  • Amgen, Inc.
  • Xilis, Inc
• Publications & Artistic Works
• 

  Selected Publications

  • Academic Articles

    • Wang, Jiangbo, Robert A. Mook, Xiu-Rong Ren, Qingfu Zhang, Genevieve Jing, Min Lu, Ivan Spasojevic, H Kim Lyerly, David Hsu, and Wei Chen. “Identification of DK419, a potent inhibitor of Wnt/β-catenin signaling and colorectal cancer growth.” Bioorg Med Chem 26, no. 20 (November 1, 2018): 5435–42. https://doi.org/10.1016/j.bmc.2018.09.016.
       Full Text  Link to Item
    • Bu, Pengcheng, Kai-Yuan Chen, Kun Xiang, Christelle Johnson, Scott B. Crown, Nikolai Rakhilin, Yiwei Ai, et al. “Aldolase B-Mediated Fructose Metabolism Drives Metabolic Reprogramming of Colon Cancer Liver Metastasis.” Cell Metab 27, no. 6 (June 5, 2018): 1249-1262.e4. https://doi.org/10.1016/j.cmet.2018.04.003.
       Full Text  Link to Item
    • Lu, Min, Amelia S. Zessin, Wayne Glover, and David S. Hsu. “Activation of the mTOR Pathway by Oxaliplatin in the Treatment of Colorectal Cancer Liver Metastasis.” Plos One 12, no. 1 (2017): e0169439. https://doi.org/10.1371/journal.pone.0169439.
       Full Text  Link to Item
    • Zhang, Tian, Rengasamy Boominathan, Brad Foulk, Chandra Rao, Gabor Kemeny, John H. Strickler, James L. Abbruzzese, et al. “Development of a Novel c-MET-Based CTC Detection Platform.” Mol Cancer Res 14, no. 6 (June 2016): 539–47. https://doi.org/10.1158/1541-7786.MCR-16-0011.
       Full Text  Open Access Copy  Link to Item
    • Mi, Jing, Partha Ray, Jenny Liu, Chien-Tsun Kuan, Jennifer Xu, David Hsu, Bruce A. Sullenger, Rebekah R. White, and Bryan M. Clary. “In Vivo Selection Against Human Colorectal Cancer Xenografts Identifies an Aptamer That Targets RNA Helicase Protein DHX9.” Mol Ther Nucleic Acids 5 (April 26, 2016): e315. https://doi.org/10.1038/mtna.2016.27.
       Full Text  Link to Item
    • Tang, Xiaohu, Jianli Wu, Chien-Kuang Ding, Min Lu, Melissa M. Keenan, Chao-Chieh Lin, Chih-An Lin, et al. “Cystine Deprivation Triggers Programmed Necrosis in VHL-Deficient Renal Cell Carcinomas.” Cancer Res 76, no. 7 (April 1, 2016): 1892–1903. https://doi.org/10.1158/0008-5472.CAN-15-2328.
       Full Text  Link to Item
    • Bu, Pengcheng, Lihua Wang, Kai-Yuan Chen, Nikolai Rakhilin, Jian Sun, Adria Closa, Kuei-Ling Tung, et al. “miR-1269 promotes metastasis and forms a positive feedback loop with TGF-β.” Nat Commun 6 (April 15, 2015): 6879. https://doi.org/10.1038/ncomms7879.
       Full Text  Link to Item
    • Zhang, Tian, Elizabeth L. Boswell, Shannon J. McCall, and David S. Hsu. “Mismatch repair gone awry: Management of Lynch syndrome.” Crit Rev Oncol Hematol 93, no. 3 (March 2015): 170–79. https://doi.org/10.1016/j.critrevonc.2014.10.005.
       Full Text  Link to Item
    • Ganapathi, Asvin M., Paul J. Speicher, Brian R. Englum, Anthony W. Castleberry, John Migaly, David S. Hsu, and Christopher R. Mantyh. “Adjuvant chemotherapy for t1 node-positive colon cancers provides significant survival benefit.” Dis Colon Rectum 57, no. 12 (December 2014): 1341–48. https://doi.org/10.1097/DCR.0000000000000245.
       Full Text  Link to Item
    • Rangwala, Fatima, Johanna C. Bendell, Mark F. Kozloff, Christy C. Arrowood, Andrew Dellinger, Jennifer Meadows, Sandra Tourt-Uhlig, et al. “Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors.” Invest New Drugs 32, no. 4 (August 2014): 700–709. https://doi.org/10.1007/s10637-014-0089-2.
       Full Text  Link to Item
    • Zhang, Jenny, Dereje Jima, Andrea B. Moffitt, Qingquan Liu, Magdalena Czader, Eric D. Hsi, Yuri Fedoriw, et al. “The genomic landscape of mantle cell lymphoma is related to the epigenetically determined chromatin state of normal B cells.” Blood 123, no. 19 (May 8, 2014): 2988–96. https://doi.org/10.1182/blood-2013-07-517177.
       Full Text  Link to Item
    • Strickler, John H., Shannon McCall, Andrew B. Nixon, John C. Brady, Herbert Pang, Christel Rushing, Allen Cohn, et al. “Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer.” Invest New Drugs 32, no. 2 (April 2014): 330–39. https://doi.org/10.1007/s10637-013-0042-9.
       Full Text  Link to Item
    • Morse, Michael A., Donna Niedzwiecki, John L. Marshall, Christopher Garrett, David Z. Chang, Mebea Aklilu, Todd S. Crocenzi, et al. “A randomized phase II study of immunization with dendritic cells modified with poxvectors encoding CEA and MUC1 compared with the same poxvectors plus GM-CSF for resected metastatic colorectal cancer.” Ann Surg 258, no. 6 (December 2013): 879–86. https://doi.org/10.1097/SLA.0b013e318292919e.
       Full Text  Link to Item
    • Morse, Michael A., Arvind Chaudhry, Elizabeth S. Gabitzsch, Amy C. Hobeika, Takuya Osada, Timothy M. Clay, Andrea Amalfitano, et al. “Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients.” Cancer Immunol Immunother 62, no. 8 (August 2013): 1293–1301. https://doi.org/10.1007/s00262-013-1400-3.
       Full Text  Link to Item
    • Zani, Sabino, Katia Papalezova, Sandra Stinnett, Douglas Tyler, David Hsu, and Dan G. Blazer. “Modest advances in survival for patients with colorectal-associated peritoneal carcinomatosis in the era of modern chemotherapy.” J Surg Oncol 107, no. 4 (March 2013): 307–11. https://doi.org/10.1002/jso.23222.
       Full Text  Link to Item
    • Mettu, N. B., H. Hurwitz, and D. S. Hsu. “Use of molecular biomarkers to inform adjuvant therapy for colon cancer.” Oncology (United States) 27, no. 8 (January 1, 2013).
    • Uronis, Hope E., Johanna C. Bendell, Ivy Altomare, Gerard C. Blobe, S David Hsu, Michael A. Morse, Herbert Pang, et al. “A phase II study of capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas.” Oncologist 18, no. 3 (2013): 271–72. https://doi.org/10.1634/theoncologist.2012-0404.
       Full Text  Link to Item
    • Kim, Mickey K., Takuya Osada, William T. Barry, Xiao Yi Yang, Jennifer A. Freedman, Katherine A. Tsamis, Michael Datto, et al. “Characterization of an oxaliplatin sensitivity predictor in a preclinical murine model of colorectal cancer.” Mol Cancer Ther 11, no. 7 (July 2012): 1500–1509. https://doi.org/10.1158/1535-7163.MCT-11-0937.
       Full Text  Link to Item
    • Riedel, Richard F., Alessandro Porrello, Emily Pontzer, Emily J. Chenette, David S. Hsu, Bala Balakumaran, Anil Potti, Joseph Nevins, and Phillip C. Febbo. “Retraction in part: A genomic approach to identify molecular pathways associated with chemotherapy resistance.” Mol Cancer Ther 11, no. 5 (May 2012): 1214–15. https://doi.org/10.1158/1535-7163.MCT-12-0210.
       Full Text  Link to Item
    • Levine, Edward A., Dan G. Blazer, Mickey K. Kim, Perry Shen, John H. Stewart, Cynthia Guy, and David S. Hsu. “Gene expression profiling of peritoneal metastases from appendiceal and colon cancer demonstrates unique biologic signatures and predicts patient outcomes.” J Am Coll Surg 214, no. 4 (April 2012): 599–606. https://doi.org/10.1016/j.jamcollsurg.2011.12.028.
       Full Text  Link to Item
    • Acharya, Chaitanya R., David S. Hsu, Carey K. Anders, Ariel Anguiano, Kelly H. Salter, Kelli S. Walters, Richard C. Redman, et al. “Retraction: Acharya CR, et al. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer. JAMA. 2008;299(13):1574-1587.” Jama 307, no. 5 (February 1, 2012): 453. https://doi.org/10.1001/jama.2012.2.
       Full Text  Link to Item
    • Uronis, Joshua M., Takuya Osada, Shannon McCall, Xiao Yi Yang, Christopher Mantyh, Michael A. Morse, H Kim Lyerly, Bryan M. Clary, and David S. Hsu. “Histological and molecular evaluation of patient-derived colorectal cancer explants.” Plos One 7, no. 6 (2012): e38422. https://doi.org/10.1371/journal.pone.0038422.
       Full Text  Link to Item
    • Deusen, J. van, and D. S. Hsu. “Predictive and prognostic biomarkers in colorectal cancer.” Frontiers in Biology 6, no. 6 (December 1, 2011): 482–89. https://doi.org/10.1007/s11515-011-1158-y.
       Full Text
    • Garman, Katherine S., Chaitanya R. Acharya, Elena Edelman, Marian Grade, Jochen Gaedcke, Shivani Sud, William Barry, et al. “Retraction for Garman et al: A genomic approach to colon cancer risk stratification yields biologic insights into therapeutic opportunities.” Proc Natl Acad Sci U S A 108, no. 42 (October 18, 2011): 17569. https://doi.org/10.1073/pnas.1115170108.
       Full Text  Link to Item
    • Freedman, Jennifer A., Christina K. Augustine, Angelica M. Selim, Kirsten C. Holshausen, Zhengzheng Wei, Katherine A. Tsamis, David S. Hsu, et al. “A methodology for utilization of predictive genomic signatures in FFPE samples.” Bmc Med Genomics 4 (July 11, 2011): 58. https://doi.org/10.1186/1755-8794-4-58.
       Full Text  Link to Item
    • Osada, Takuya, Minyong Chen, Xiao Yi Yang, Ivan Spasojevic, Jeffrey B. Vandeusen, David Hsu, Bryan M. Clary, et al. “Antihelminth compound niclosamide downregulates Wnt signaling and elicits antitumor responses in tumors with activating APC mutations.” Cancer Res 71, no. 12 (June 15, 2011): 4172–82. https://doi.org/10.1158/0008-5472.CAN-10-3978.
       Full Text  Link to Item
    • Altomare, Ivy, Johanna C. Bendell, Karen E. Bullock, Hope E. Uronis, Michael A. Morse, S David Hsu, S Yousuf Zafar, et al. “A phase II trial of bevacizumab plus everolimus for patients with refractory metastatic colorectal cancer.” Oncologist 16, no. 8 (2011): 1131–37. https://doi.org/10.1634/theoncologist.2011-0078.
       Full Text  Link to Item
    • Hsu, D. S., C. R. Acharya, B. S. Balakumaran, R. F. Riedel, M. K. Kim, M. Stevenson, S. Tuchman, et al. “Characterizing the developmental pathways TTF-1, NKX2-8, and PAX9 in lung cancer (Proceedings of the National Academy of Sciences of the United States of America (2009) 106, 13 (5312-5317) DOI: 10.1073/pnas.0900827106).” Proceedings of the National Academy of Sciences of the United States of America 108, no. 35 (2011): 14705-. https://doi.org/10.1073/pnas.1111196108.
       Full Text
    • Wang, Xinhui, Takuya Osada, Yangyang Wang, Ling Yu, Koichi Sakakura, Akihiro Katayama, James B. McCarthy, et al. “CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer.” J Natl Cancer Inst 102, no. 19 (October 6, 2010): 1496–1512. https://doi.org/10.1093/jnci/djq343.
       Full Text  Link to Item
    • Hsu, David S., Mickey K. Kim, Bala S. Balakumaran, Chaitanya R. Acharya, Carey K. Anders, Tim Clay, H Kim Lyerly, Charles G. Drake, Michael A. Morse, and Phillip G. Febbo. “Immune signatures predict prognosis in localized cancer.” Cancer Invest 28, no. 7 (August 2010): 765–73. https://doi.org/10.3109/07357900903095755.
       Full Text  Link to Item
    • Osada, T., D. Hsu, S. Hammond, A. Hobeika, G. Devi, T. M. Clay, H. K. Lyerly, and M. A. Morse. “Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEA/CD3-bispecific T-cell-engaging BiTE antibody.” Br J Cancer 102, no. 1 (January 5, 2010): 124–33. https://doi.org/10.1038/sj.bjc.6605364.
       Full Text  Link to Item
    • Balakumaran, Bala S., Alessandro Porrello, David S. Hsu, Wayne Glover, Adam Foye, Janet Y. Leung, Beth A. Sullivan, William C. Hahn, Massimo Loda, and Phillip G. Febbo. “MYC activity mitigates response to rapamycin in prostate cancer through eukaryotic initiation factor 4E-binding protein 1-mediated inhibition of autophagy.” Cancer Res 69, no. 19 (October 1, 2009): 7803–10. https://doi.org/10.1158/0008-5472.CAN-09-0910.
       Full Text  Open Access Copy  Link to Item
    • Hsu, David S., Chaitanya R. Acharya, Bala S. Balakumaran, Richard F. Riedel, Mickey K. Kim, Marvaretta Stevenson, Sascha Tuchman, et al. “Characterizing the developmental pathways TTF-1, NKX2-8, and PAX9 in lung cancer.” Proc Natl Acad Sci U S A 106, no. 13 (March 31, 2009): 5312–17. https://doi.org/10.1073/pnas.0900827106.
       Full Text  Link to Item
    • Garman, K. S., C. R. Acharya, E. Edelman, M. Grade, J. Gaedcke, S. Sud, W. Barry, et al. “Erratum: A genomic approach to colon cancer risk stratification yields biologic insights into therapeutic opportunities (Proceedings of the National Academy of Sciences of the United States of America (2008) 105:49 (19432-19437) Doi: 10.1073/pnas.0806674105).” Proceedings of the National Academy of Sciences of the United States of America 106, no. 16 (2009): 6878-. https://doi.org/10.1073/pnas.0902004106.
       Full Text
    • Garman, Katherine S., Chaitanya R. Acharya, Elena Edelman, Marian Grade, Jochen Gaedcke, Shivani Sud, William Barry, et al. “A genomic approach to colon cancer risk stratification yields biologic insights into therapeutic opportunities.” Proc Natl Acad Sci U S A 105, no. 49 (December 9, 2008): 19432–37. https://doi.org/10.1073/pnas.0806674105.
       Full Text  Link to Item
    • Riedel, Richard F., Alessandro Porrello, Emily Pontzer, Emily J. Chenette, David S. Hsu, Bala Balakumaran, Anil Potti, Joseph Nevins, and Phillip G. Febbo. “A genomic approach to identify molecular pathways associated with chemotherapy resistance.” Mol Cancer Ther 7, no. 10 (October 2008): 3141–49. https://doi.org/10.1158/1535-7163.MCT-08-0642.
       Full Text  Link to Item
    • Anders, Carey K., David S. Hsu, Gloria Broadwater, Chaitanya R. Acharya, John A. Foekens, Yi Zhang, Yixin Wang, et al. “Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression.” J Clin Oncol 26, no. 20 (July 10, 2008): 3324–30. https://doi.org/10.1200/JCO.2007.14.2471.
       Full Text  Link to Item
    • Acharya, Chaitanya R., David S. Hsu, Carey K. Anders, Ariel Anguiano, Kelly H. Salter, Kelli S. Walters, Richard C. Redman, et al. “Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer.” Jama 299, no. 13 (April 2, 2008): 1574–87. https://doi.org/10.1001/jama.299.13.1574.
       Full Text  Link to Item
    • Anders, Carey K., Chaitanya R. Acharya, David S. Hsu, Gloria Broadwater, Katherine Garman, John A. Foekens, Yi Zhang, et al. “Age-specific differences in oncogenic pathway deregulation seen in human breast tumors.” Plos One 3, no. 1 (January 2, 2008): e1373. https://doi.org/10.1371/journal.pone.0001373.
       Full Text  Open Access Copy  Link to Item
    • Hsu, David S., Bala S. Balakumaran, Chaitanya R. Acharya, Vanja Vlahovic, Kelli S. Walters, Katherine Garman, Carey Anders, et al. “Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer.” J Clin Oncol 25, no. 28 (October 1, 2007): 4350–57. https://doi.org/10.1200/JCO.2007.11.0593.
       Full Text  Link to Item
    • Thresher, R. J., M. H. Vitaterna, Y. Miyamoto, A. Kazantsev, D. S. Hsu, C. Petit, C. P. Selby, et al. “Role of mouse cryptochrome blue-light photoreceptor in circadian photoresponses.” Science 282, no. 5393 (November 20, 1998): 1490–94. https://doi.org/10.1126/science.282.5393.1490.
       Full Text  Link to Item
    • Zhao, X., J. Liu, D. S. Hsu, S. Zhao, J. S. Taylor, and A. Sancar. “Reaction mechanism of (6-4) photolyase.” J Biol Chem 272, no. 51 (December 19, 1997): 32580–90. https://doi.org/10.1074/jbc.272.51.32580.
       Full Text  Link to Item
    • Mu, D., M. Wakasugi, D. S. Hsu, and A. Sancar. “Characterization of reaction intermediates of human excision repair nuclease.” J Biol Chem 272, no. 46 (November 14, 1997): 28971–79. https://doi.org/10.1074/jbc.272.46.28971.
       Full Text  Link to Item
    • Hsu, D. S., X. Zhao, S. Zhao, A. Kazantsev, R. P. Wang, T. Todo, Y. F. Wei, and A. Sancar. “Putative human blue-light photoreceptors hCRY1 and hCRY2 are flavoproteins.” Biochemistry 35, no. 44 (November 5, 1996): 13871–77. https://doi.org/10.1021/bi962209o.
       Full Text  Link to Item
    • Mu, D., D. S. Hsu, and A. Sancar. “Reaction mechanism of human DNA repair excision nuclease.” J Biol Chem 271, no. 14 (April 5, 1996): 8285–94. https://doi.org/10.1074/jbc.271.14.8285.
       Full Text  Link to Item
    • Ozer, Z., J. T. Reardon, D. S. Hsu, K. Malhotra, and A. Sancar. “The other function of DNA photolyase: stimulation of excision repair of chemical damage to DNA.” Biochemistry 34, no. 49 (December 12, 1995): 15886–89. https://doi.org/10.1021/bi00049a002.
       Full Text  Link to Item
    • Hsu, D. S., S. T. Kim, Q. Sun, and A. Sancar. “Structure and function of the UvrB protein.” J Biol Chem 270, no. 14 (April 7, 1995): 8319–27. https://doi.org/10.1074/jbc.270.14.8319.
       Full Text  Link to Item
    • Mu, D., C. H. Park, T. Matsunaga, D. S. Hsu, J. T. Reardon, and A. Sancar. “Reconstitution of human DNA repair excision nuclease in a highly defined system.” J Biol Chem 270, no. 6 (February 10, 1995): 2415–18. https://doi.org/10.1074/jbc.270.6.2415.
       Full Text  Link to Item
    • Huang, J. C., D. S. Hsu, A. Kazantsev, and A. Sancar. “Substrate spectrum of human excinuclease: repair of abasic sites, methylated bases, mismatches, and bulky adducts.” Proc Natl Acad Sci U S A 91, no. 25 (December 6, 1994): 12213–17. https://doi.org/10.1073/pnas.91.25.12213.
       Full Text  Link to Item
    • Hsu, D. S., M. Takahashi, E. Delagoutte, E. Bertrand-Burggraf, Y. H. Wang, B. Norden, R. P. Fuchs, J. Griffith, and A. Sancar. “Flow linear dichroism and electron microscopic analysis of protein-DNA complexes of a mutant UvrB protein that binds to but cannot kink DNA.” J Mol Biol 241, no. 5 (September 2, 1994): 645–50. https://doi.org/10.1006/jmbi.1994.1541.
       Full Text  Link to Item

  • Book Sections

    • Hsu, D. S., M. Morse, T. Clay, G. Devi, and H. Kim Lyerly. “Immune Cells and the Tumor Microenvironment.” In Genomic and Personalized Medicine, Two-Vol Set, 818–29, 2009. https://doi.org/10.1016/B978-0-12-369420-1.00068-8.
       Full Text

  • Other Articles

    • “Retraction. Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer. J Clin Oncol 25:4350–7, 2007.” J Clin Oncol, December 10, 2010. https://doi.org/10.1200/JCO.2010.33.7311.
       Full Text  Link to Item
• Teaching & Mentoring
• 

  Recent Courses

  • MOLMED 301B: Research in MOLMED - Oncological Sciences 2021
  • MOLMED 302B: Research in MOLMED - Regenerative Medicine 2021
  • MOLMED 303B: Research in MOLMED - Molecular Basis of Disease 2021
  • MOLMED 304B: Research in MOLMED - Nutritional & Metabolic mechanisms of Chronic Diseases 2021
  • MOLMED 301B: Research in MOLMED - Oncological Sciences 2020
  • MOLMED 302B: Research in MOLMED - Regenerative Medicine 2020
  • MOLMED 303B: Research in MOLMED - Molecular Basis of Disease 2020
  • MOLMED 304B: Research in MOLMED - Nutritional & Metabolic mechanisms of Chronic Diseases 2020
  • MOLMED 305B: Research in MOLMED - Translational Pharmacology 2020
  • MOLMED 301B: Research in MOLMED - Oncological Sciences 2019
  • MOLMED 302B: Research in MOLMED - Regenerative Medicine 2019
  • MOLMED 303B: Research in MOLMED - Molecular Basis of Disease 2019
  • MOLMED 304B: Research in MOLMED - Nutritional & Metabolic mechanisms of Chronic Diseases 2019
  • MOLMED 305B: Research in MOLMED - Translational Pharmacology 2019

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.